Drugs / AXV-101
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 0 | NCT07269665 | May 2026 → Feb 2027 expected | Bardet-Biedl syndrome 1, retinal degeneration | Axovia Therapeutics | Not yet recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | AXV-101 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07269665 ↗ |
| Route | Other | “being injected into the eye” NCT07269665 ↗ |